The 100% Pharma Tariff: What Every Importer Must Know Before July 31

In 37 days, the United States will impose a 100% tariff on patented pharmaceutical imports — the highest Section 232 rate ever applied to a single product category. If you import APIs, key starting materials, or finished drugs classified under Chapters 29 or 30 of the HTSUS, your landed cost is about to double. Here's your complete guide to what's covered, what's exempt, and the five things you need to do this week.

On April 2, 2026, President Trump signed Proclamation 11020 — and the pharmaceutical import world split in two.

On one side: 17 of the world's largest drug companies — AbbVie, Pfizer, Novo Nordisk, Eli Lilly, Johnson & Johnson, and 12 others — who face a 100% tariff on their patented pharmaceutical imports starting July 31, 2026. On the other: every other pharmaceutical importer in the country, who gets an extra 60 days (until September 29) before the same rate hits them.

The numbers are staggering. The U.S. imported approximately $200 billion in pharmaceutical products in 2025. A 100% duty doesn't just increase costs — it fundamentally breaks import economics for any company that hasn't secured one of the limited exemptions or negotiated an onshoring deal with the Commerce Department. And the application window for those deals? It closed on June 12.

What Section 232 Pharmaceutical Tariffs Actually Cover

The proclamation covers three product categories, all defined by reference to Annex I, which modifies the HTSUS across more than 130 specified subheadings spanning two chapters:

• Chapter 29 (Organic Chemicals) — active pharmaceutical ingredients and key starting materials
• Chapter 30 (Pharmaceutical Products) — finished patented drug products and biologics

The critical qualifier: these tariffs apply only to patented pharmaceuticals and their associated ingredients. The patent status is determined by FDA Orange Book or Purple Book listings. If your product's active ingredient is covered by a valid patent and classifiable under one of the Annex I subheadings, you're in scope.

Products NOT covered (at least for now):

• Generic pharmaceuticals and their associated ingredients
• Biosimilar products
• Orphan drugs
• Nuclear medicines
• Plasma-derived therapies
• Fertility treatments
• Cell and gene therapies
• Antibody drug conjugates
• U.S.-origin products (manufactured domestically and re-imported)

That generic exclusion comes with a warning label: the proclamation requires the Commerce Secretary to reassess within one year whether generics should be added. If you're importing generic APIs from India or China, don't assume permanent immunity.

The Tiered Rate Structure: Who Pays What

This isn't a simple flat tariff. Proclamation 11020 created one of the most complex duty frameworks in modern U.S. trade law — a tiered system where your rate depends on who you are, where your goods come from, and what deals you've struck with the government.

The floating rate mechanism adds another layer of complexity. The Section 232 tariff operates as a cumulative rate: if your product already carries a non-zero MFN duty under Column 1, the Section 232 rate is reduced so the total duty burden equals 100%. If your Column 1 rate already exceeds 100%, only the Column 1 rate applies.

Example: A patented API classified under 2934.99.39 carries a Column 1 rate of 6.5%. Your Section 232 rate would be 93.5% — bringing your total to exactly 100%.

The 17 Named Companies: First Wave on July 31

The Annex III companies face the earliest deadline. Here's the full list:

1. AbbVie Inc.
2. Amgen Inc.
3. AstraZeneca Pharmaceuticals, LP
4. Bristol Myers Squibb
5. Boehringer Ingelheim Pharmaceuticals, Inc.
6. Eli Lilly and Company
7. EMD Serono, Inc.
8. Genentech, Inc.
9. Gilead Sciences, Inc.
10. GlaxoSmithKline LLC and ViiV Healthcare Company
11. Johnson & Johnson
12. Merck Sharp & Dohme LLC
13. Novartis Pharmaceuticals Corporation
14. Novo Nordisk Inc.
15. Pfizer Inc.
16. Regeneron Pharmaceuticals, Inc.
17. Sanofi S.A.

Why this matters to you even if you're not one of these companies: Many customs brokers and freight forwarders handle entries for these manufacturers or their contract manufacturers. If you're filing entries on behalf of any Annex III company after July 31, you need to apply the correct Section 232 duty rate. Getting it wrong is a misclassification — and under the new Customs Enforcement Executive Order, penalties for negligent misclassification start at a much higher floor.

The Onshoring Application Window: What You Missed (and What's Still Possible)

On May 13, 2026, the Commerce Department's Bureau of Industry and Security (BIS) published procedures for pharmaceutical manufacturers to apply for company-specific onshoring agreements. The application deadline was June 12, 2026 — already passed.

Here's what applicants had to commit to:

• Detailed capital investment plans for U.S. manufacturing facilities
• Production volume commitments and timelines
• Compliance monitoring and reporting requirements
• Average estimated application time: 8 hours per submission

Companies with approved onshoring agreements get the 20% rate instead of 100%. Add an MFN pricing agreement with HHS (agreeing to sell the drug at the lowest price offered to any country), and the rate drops to 0% through January 20, 2029.

If you missed the June 12 deadline, the proclamation doesn't explicitly foreclose future application rounds. Commerce has discretion to open additional windows. But for July 31 and September 29 effective dates, you're likely locked into the 100% rate unless your goods qualify for a country-specific or product-category exemption.

Foreign Trade Zones: The Rules Changed Overnight

If you use Foreign Trade Zones (FTZs) for pharmaceutical imports, pay close attention. The proclamation changed FTZ treatment for covered goods:

Pharmaceutical products admitted to an FTZ after the effective date must enter under privileged foreign status. This locks in the duty rate at the time of admission — meaning you cannot use an FTZ to defer or avoid Section 232 pharmaceutical tariffs by holding goods in zone status and waiting for a rate reduction.

For goods already admitted to an FTZ before July 31 under non-privileged foreign status, the treatment is less clear. Consult with your FTZ operator and customs counsel immediately to determine whether re-designation is required.

Classification Landmines: Where Importers Will Get Burned

The 130+ HTSUS subheadings in Annex I don't cover every product in Chapters 29 and 30. This creates a dangerous gray zone where classification determines whether you pay 100% or 0%.

Common classification traps:

• Intermediates vs. key starting materials: A chemical intermediate one synthesis step removed from an API may or may not fall under a covered subheading. The distinction between 2933 (heterocyclic compounds) and 2934 (nucleic acids) subheadings matters enormously.
• Combination products: A drug-device combination classified under Chapter 30 as a pharmaceutical preparation triggers the tariff. The same product classified under Chapter 90 (medical instruments) does not.
• Bulk vs. dosage form: An API imported in bulk under Chapter 29 and a finished dosage form under Chapter 30 may carry different covered/uncovered statuses depending on the specific 8-digit HTSUS code.
• Patent expiration timing: If a drug's patent expires between now and your import date, the generic exclusion may apply. But you'll need documentation — the CBP won't take your word for it.

The bottom line: If you haven't done a full HTSUS portfolio review of your pharmaceutical imports against the Annex I list, you're flying blind into a 100% tariff.

Drawback Is Available — Use It

One piece of good news: duty drawback is explicitly available for Section 232 pharmaceutical tariffs. If you import patented APIs, manufacture finished drugs in the U.S., and export those drugs, you can recover up to 99% of the Section 232 duties paid.

This matters most for contract manufacturers who import ingredients and export finished products. At a 100% duty rate, drawback recovery could represent millions in recaptured costs per quarter.

File your drawback claims promptly — CBP processing times for drawback have been running 12-18 months, and the sooner you establish your claim, the sooner you'll see cash back.

Five Things to Do This Week

1. Audit your HTSUS portfolio against Annex I — Pull every pharmaceutical import line from the past 12 months. Cross-reference each 8-digit HTSUS code against the Annex I covered list. Identify which entries would be subject to 100% duties if imported after July 31.

2. Verify patent status of every covered product — Check FDA Orange Book and Purple Book listings. Products whose patents expire before your next import may qualify for the generic exclusion. Document everything — you'll need it if CBP challenges your classification.

3. Evaluate country-of-origin for reduced rates — If your API supplier has manufacturing in the EU, Japan, Korea, Switzerland, or the UK, the country-specific reduced rates (10-15%) apply. Origin determination follows standard substantial transformation rules — mixing or repackaging doesn't count.

4. Review FTZ strategy immediately — If you're holding pharmaceutical inventory in an FTZ, consult counsel on whether goods admitted before July 31 retain non-privileged status. For future admissions, model the cost impact of privileged foreign status.

5. Set up drawback tracking now — If you export any portion of your pharmaceutical production, implement a drawback tracking system before the tariffs hit. You can't file drawback claims retroactively without import-to-export matching records.

What's Coming Next

Several developments will shape how these tariffs evolve:

• July 1, 2026: Commerce Department status report to the President on onshoring negotiations. This could signal whether additional application rounds will open or whether rates will be modified.
• July 31, 2026: First wave effective date for Annex III companies.
• September 29, 2026: Second wave for all other companies.
• Within 1 year (by April 2, 2027): Commerce Secretary reassessment of whether generic pharmaceuticals should be brought into scope.
• January 20, 2029: Zero-rate treatment for onshoring + MFN companies expires.
• April 2, 2030: Reduced 20% onshoring rate escalates back to 100%.

The Commerce Department's July 1 report is the one to watch. If onshoring negotiations are proceeding slowly — and with only a month between the June 12 application deadline and the report date, they almost certainly are — the administration may signal flexibility on timelines or rates.

The Classification Advantage

The complexity of this tariff regime — 130+ subheadings, patent-dependent coverage, country-specific rates, floating rate mechanisms, FTZ rules — makes accurate HTS classification more consequential than ever. A single digit wrong in your tariff code could mean the difference between 0% and 100% duty.

This is where automated classification tools earn their keep. TariffLens can cross-reference your pharmaceutical imports against the Annex I covered list and flag exposure before your next entry — not after CBP sends you a rate advance.

This article is for informational purposes only and does not constitute legal, tax, or customs advice. Consult a licensed customs broker or trade attorney for guidance specific to your situation.